BTdCPU Datasheet DC Chemicals
Description BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.
Cat.No DC32550
Name BTdCPU

Chemical Properties

CAS 1257423-87-2
Formula C13H8CL2N4OS
MW 339.194
Storage

References

[1]. Burwick N, et al. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com